Role of Peroxisome Proliferator-Activated Receptor-γ in the Glucose-Sensing Apparatus of Liver and β-Cells

Diabetes

Volumn 53, Issue SUPPL. 1, 2004, Pages

  Kim, Ha Il ^a   Ahn, Yong Ho ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BETA GLUCOKINASE; GLUCOKINASE; GLUCOSE TRANSPORTER 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; CONFERENCE PAPER; DRUG MECHANISM; ENZYME ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; LIVER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS CELL; PRIORITY JOURNAL; PROMOTER REGION;

EID: 0842263985     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.2007.s60     Document Type: Conference Paper

References (49)

1. Saltiel AR: New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104:517-529, 2001
2. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Staels B, Auwerx J, Laville M, Vidal H: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46:1319-1327, 1997
3. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
4. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS: Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 100:530-537, 1997
5. Sreenan S, Sturis J, Pugh W, Burant CF, Polonsky KS: Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am J Physiol 271:E742-E747, 1996
6. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD: Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137:4189-4195, 1996
7. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S: Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880-883, 1999
8. Auwerx J: PPARgamma, the ultimate thrifty gene. Diabetologia 42:1033-1049, 1999
9. Spiegelman BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514, 1998
10. Iwata M, Haruta T, Usui I, Takata Y, Takano A, Uno T, Kawahara J, Ueno E, Sasaoka T, Ishibashi O, Kobayashi M: Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-gamma. Diabetes 50:1083-1092, 2001
11. Smith U, Gogg S, Johansson A, Olausson T, Rotter V, Svalstedt B: Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB J 15:215-220, 2001
12. Rieusset J, Auwerx J, Vidal H: Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun 265:265-271, 1999
13. Ribon V, Johnson JH, Camp HS, Saltiel AR: Thiazolidinediones and insulin resistance: peroxisome proliferator activated receptor gamma activation stimulates expression of the CAP gene. Proc Natl Acad Sci U S A 95:14751-14756, 1998
14. Baumann CA, Chokshi N, Saltiel AR, Ribon V: Cloning and characterization of a functional peroxisome proliferator activator receptor-gamma-responsive element in the promoter of the CAP gene. J Biol Chem 275:9131-9135, 2000
15. Zhang B, Szalkowski D, Diaz E, Hayes N, Smith R, Berger J: Potentiation of insulin stimulation of phosphatidylinositol 3-kinase by thiazolidinedione-derived antidiabetic agents in Chinese hamster ovary cells expressing human insulin receptors and L6 myotubes. J Biol Chem 269:25735-25741, 1994
16. Kausch C, Krutzfeldt J, Witke A, Rettig A, Bachmann O, Rett K, Matthaei S, Machicao F, Haring HU, Stumvoll M: Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells. Biochem Biophys Res Commun 280:664-674, 2001
17. Cha BS, Ciaraldi TP, Carter L, Nikoulina SE, Mudaliar S, Mukherjee R, Paterniti JR Jr, Henry RR: Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle. Diabetologia 44:444-452, 2001
18. Schuit FC, Huypens P, Heimberg H, Pipeleers DG: Glucose sensing in pancreatic beta-cells: a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus. Diabetes 50:1-11, 2001
19. Magnuson MA: Glucokinase gene structure: functional implications of molecular genetic studies. Diabetes 39:523-527, 1990
20. Matschinsky FM, Magnuson MA: Molecular pathogenesis of MODYs. In Frontiers in Diabetes. Vol. 15. Belfiore F, Ed. Basel, Karger, 2000
21. Thorens B, Guillam MT, Beermann F, Burcelin R, Jaquet M: Transgenic reexpression of GLUT1 or GLUT2 in pancreatic beta cells rescues GLUT2-null mice from early death and restores normal glucose-stimulated insulin secretion. J Biol Chem 275:23751-23758, 2000
22. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, Shelton KD, Lindner J, Cherrington AD, Magnuson MA: Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem 274:305-315, 1999
23. Faradji RN, Havari E, Chen Q, Gray J, Tornheim K, Corkey BE, Mulligan RC, Lipes MA: Glucose-induced toxicity in insulin-producing pituitary cells that coexpress GLUT2 and glucokinase: implications for metabolic engineering. J Biol Chem 276:36695-36702, 2001
24. Girard J, Ferre P, Foufelle F: Mechanisms by which carbohydrates regulate expression of genes for glycolytic and lipogenic enzymes. Annu Rev Nutr 17:325-352, 1997
25. Aiston S, Trinh KY, Lange AJ, Newgard CB, Agius L: Glucose-6-phosphatase overexpression lowers glucose 6-phosphate and inhibits glycogen synthesis and glycolysis in hepatocytes without affecting glucokinase translocation: evidence against feedback inhibition of glucokinase. J Biol Chem 274:24559-24566, 1999
26. Ferre T, Riu E, Bosch F, Valera A: Evidence from transgenic mice that glucokinase is rate limiting for glucose utilization in the liver. FASEB J 10:1213-1218, 1996
27. Hariharan N, Farrelly D, Hagan D, Hillyer D, Arbeeny C, Sabrah T, Treloar A, Brown K, Kalinowski S, Mookhtiar K: Expression of human hepatic glucokinase in transgenic mice liver results in decreased glucose levels and reduced body weight. Diabetes 46:11-16, 1997
28. Niswender KD, Shiota M, Postic C, Cherrington AD, Magnuson MA: Effects of increased glucokinase gene copy number on glucose homeostasis and hepatic glucose metabolism. J Biol Chem 272:22570-22575, 1997
29. Burcelin R, del Carmen Munoz M, Guillam MT, Thorens B: Liver hyperplasia and paradoxical regulation of glycogen metabolism and glucose-sensitive gene expression in GLUT2-null hepatocytes: further evidence for the existence of a membrane-based glucose release pathway. J Biol Chem 275:10930-10936, 2000
30. Dubois M, Pattou F, Kerr-Conte J, Gmyr V, Vandewalle B, Desreumaux P, Auwerx J, Schoonjans K, Lefebvre J: Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 43:1165-1169, 2000
31. Laybutt R, Hasenkamp W, Groff A, Grey S, Jonas JC, Kaneto H, Sharma A, Bonner-Weir S, Weir G: Beta-cell adaptation to hyperglycemia. Diabetes 50 (Suppl. 1):S180-S181, 2001
32. Jia DM, Otsuki M: Troglitazone stimulates pancreatic growth in normal rats. Pancreas 24:303-312, 2002
33. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA, Ramachandran RK, Willson TM, Kliewer SA: Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142:1269-1277, 2001
34. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
35. Fujiwara T, Wada M, Fukuda K, Fukami M, Yoshioka S, Yoshioka T, Horikoshi H: Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism 40:1213-1218, 1991
36. Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I, Kliewer SA, Lehmann JM, Lenhard JM, Harrington WW, Novak PJ, Faison W, Binz JG, Hashim MA, Oliver WO, Brown HR, Parks DJ, Plunket KD, Tong WQ, Menius JA, Adkison K, Noble SA, Willson TM: A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 48:1415-1424, 1999
37. Lenhard JM, Lancaster ME, Paulik MA, Weiel JE, Binz JG, Sundseth SS, Gaskill BA, Lightfoot RM, Brown HR: The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction. Diabetologia 42:545-554, 1999
38. Masuda K, Okamoto Y, Tsuura Y, Kato S, Miura T, Tsuda K, Horikoshi H, Ishida H, Seino Y: Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 38:24-30, 1995
39. Shimabukuro M, Zhou YT, Lee Y, Unger RH: Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 273:3547-3550, 1998
40. Harmon JS, Gleason CE, Tanaka Y, Oseid EA, Hunter-Berger KK, Robertson RP: In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes 48:1995-2000, 1999
41. Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, Unger RH: Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci U S A 96:11513-11518, 1999
42. Shimabukuro M, Wang MY, Zhou YT, Newgard CB, Unger RH: Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression. Proc Natl Acad Sci U S A 95:9558-9561, 1998
43. Unger RH: Lipotoxic diseases. Annu Rev Med 53:319-336, 2002
44. Kim HI, Kim JW, Kim SH, Cha JY, Kim KS, Ahn YH: Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes 49:1517-1524, 2000
45. Kim HI, Cha JY, Kim SY, Kim JW, Roh KJ, Seong JK, Lee NT, Choi KY, Kim KS, Ahn YH: Peroxisomal proliferator-activated receptor-gamma upregulates glucokinase gene expression in beta-cells. Diabetes 51:676-685, 2002
46. Palmer CN, Hsu MH, Griffin HJ, Johnson EF: Novel sequence determinants in peroxisome proliferator signaling. J Biol Chem 270:16114-16121, 1995
47. Randle PJ: Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 14:263-283, 1998
48. Burant CF, Sreenan S, Hirano K, Tai TA, Lohmiller J, Lukens J, Davidson NO, Ross S, Graves RA: Troglitazone action is independent of adipose tissue. J Clin Invest 100:2900-2908, 1997
49. Dudek RW, Kawabe T, Brinn JE, O'Brien K, Poole MC, Morgan CR: Glucose affects in vitro maturation of fetal rat islets. Endocrinology 114:582-587, 1984